OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 13 of 33

14 Anti-obesity Pharmacotherapy Anti-obesity Medication Summary Agent/Dose Description Main Side Effects/ Adverse Reactions Naltrexone/ bupropion (Contrave ER) Dose: Tablets to be taken twice daily not at meals 8 mg/90 mg increased weekly × 4 • Combination of naltrexone (opioid antagonist used for addictions) and bupropion (used for depression and smoking cessation). • Average weight loss 5-6% of body weight Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, diarrhea, and acute closure glaucoma. Bupropion can increase the risk of suicide ideation thinking in children, adolescents, and young adults (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024